Drug intelligence / Profile preview

COR-2003

Development stage: Preclinical
Lead developer: Corsera Health
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

COR-2003 is a preventive RNA interference (RNAi) medicine developed by Corsera Health. It is a small interfering RNA (siRNA) designed for once-annual administration. The drug targets angiotensinogen (AGT) to lower blood pressure, with the ultimate goal of preventing atherosclerotic cardiovascular disease (ASCVD).

Targets

AGT (O6-methylguanine-DNA methyltransferase)

Beyond the preview

Go deeper on COR-2003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COR-2003.

Explore the full profile